Molecular signature of response and potential pathways related to resistance to the HSP90 inhibitor, 17AAG, in breast cancer

Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel Agents

(2010) J. E. Dancey et al.   CLINICAL CANCER RESEARCH

A compact VEGF signature associated with distant metastases and poor outcomes

(2009) Zhiyuan Hu et al.   BMC Medicine

Acquired Resistance to 17-Allylamino-17-Demethoxygeldanamycin (17-AAG, Tanespimycin) in Glioblastoma Cells

(2009) N. Gaspar et al.   CANCER RESEARCH

CUDC-305, a Novel Synthetic HSP90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy

(2009) R. Bao et al.   CLINICAL CANCER RESEARCH

Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models

(2009) E. Caldas-Lopes et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Dual Targeting of HSC70 and HSP72 Inhibits HSP90 Function and Induces Tumor-Specific Apoptosis

(2008) Marissa V. Powers et al.   CANCER CELL

NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis

(2008) S. A. Eccles et al.   CANCER RESEARCH

Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma

(2008) D. B. Solit et al.   CLINICAL CANCER RESEARCH

Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer

(2008) Dongweon Song et al.   MOLECULAR CANCER THERAPEUTICS

Mitotic catastrophe cell death induced by heat shock protein 90 inhibitor in BRCA1-deficient breast cancer cell lines

(2008) M. Zajac et al.   MOLECULAR CANCER THERAPEUTICS

Strategies for discovering novel cancer biomarkers through utilization of emerging technologies

(2008) Vathany Kulasingam et al.   Nature clinical practice. Oncology